Ginkgo Bioworks Holdings Stock Buy Hold or Sell Recommendation
| DNA Stock | USD 6.97 0.51 7.89% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Ginkgo Bioworks Holdings is 'Strong Hold'. Macroaxis provides Ginkgo Bioworks buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding DNA positions.
Check out Ginkgo Bioworks Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Ginkgo and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Ginkgo Bioworks Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Ginkgo |
Execute Ginkgo Bioworks Buy or Sell Advice
The Ginkgo recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Ginkgo Bioworks Holdings. Macroaxis does not own or have any residual interests in Ginkgo Bioworks Holdings or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Ginkgo Bioworks' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Ginkgo Bioworks Trading Alerts and Improvement Suggestions
| Ginkgo Bioworks generated a negative expected return over the last 90 days | |
| Ginkgo Bioworks has high historical volatility and very poor performance | |
| Ginkgo Bioworks has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 227.04 M. Reported Net Loss for the year was (547.03 M) with profit before taxes, overhead, and interest of 182.5 M. | |
| Ginkgo Bioworks Holdings has about 1.32 B in cash with (319.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.84. | |
| Ginkgo Bioworks has a poor financial position based on the latest SEC disclosures | |
| Over 80.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: After Plunging -52.33 percent in 4 Weeks, Heres Why the Trend Might Reverse for Ginkgo Bioworks |
Ginkgo Bioworks Returns Distribution Density
The distribution of Ginkgo Bioworks' historical returns is an attempt to chart the uncertainty of Ginkgo Bioworks' future price movements. The chart of the probability distribution of Ginkgo Bioworks daily returns describes the distribution of returns around its average expected value. We use Ginkgo Bioworks Holdings price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Ginkgo Bioworks returns is essential to provide solid investment advice for Ginkgo Bioworks.
| Mean Return | -0.53 | Value At Risk | -9.86 | Potential Upside | 12.92 | Standard Deviation | 7.11 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Ginkgo Bioworks historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Ginkgo Stock Institutional Investors
| Shares | Forbes J M & Co | 2024-12-31 | 701.7 K | Millennium Management Llc | 2024-12-31 | 670.1 K | Two Sigma Investments Llc | 2024-12-31 | 645.4 K | Sb Investment Advisers (uk) Ltd | 2024-12-31 | 610.7 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 565.3 K | Goldman Sachs Group Inc | 2024-12-31 | 547.6 K | D. E. Shaw & Co Lp | 2024-12-31 | 546.4 K | Geode Capital Management, Llc | 2024-12-31 | 437 K | Ubs Group Ag | 2024-12-31 | 386.3 K | Bank Of America Corp | 2024-12-31 | 3.8 M | Viking Global Investors Lp | 2024-12-31 | 3.6 M |
Ginkgo Bioworks Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (67.1M) | (5M) | (67.4M) | (4.3M) | (62.2M) | (65.3M) | |
| Change In Cash | (112.6M) | 1.2B | (223.3M) | (380.0M) | (383.8M) | (364.6M) | |
| Free Cash Flow | (193.7M) | (310.3M) | (304.5M) | (336.3M) | (382.1M) | (401.2M) | |
| Depreciation | 13.9M | 29.1M | 44.4M | 71.6M | 63.0M | 42.7M | |
| Other Non Cash Items | (1.1M) | (20.9M) | (69.3M) | 266.9M | 53.0M | 41.6M | |
| Capital Expenditures | 57.8M | 56.5M | 52.3M | 40.8M | 62.5M | 53.6M | |
| Net Income | (126.7M) | (1.8B) | (2.1B) | (892.9M) | (547.0M) | (574.4M) | |
| End Period Cash Flow | 385.9M | 1.6B | 1.4B | 989.6M | 605.7M | 997.7M |
Ginkgo Bioworks Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Ginkgo Bioworks or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Ginkgo Bioworks' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Ginkgo stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.25 | |
β | Beta against Dow Jones | 2.69 | |
σ | Overall volatility | 7.29 | |
Ir | Information ratio | -0.06 |
Ginkgo Bioworks Volatility Alert
Ginkgo Bioworks Holdings is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Ginkgo Bioworks' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Ginkgo Bioworks' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Ginkgo Bioworks Fundamentals Vs Peers
Comparing Ginkgo Bioworks' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Ginkgo Bioworks' direct or indirect competition across all of the common fundamentals between Ginkgo Bioworks and the related equities. This way, we can detect undervalued stocks with similar characteristics as Ginkgo Bioworks or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Ginkgo Bioworks' fundamental indicators could also be used in its relative valuation, which is a method of valuing Ginkgo Bioworks by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Ginkgo Bioworks to competition |
| Fundamentals | Ginkgo Bioworks | Peer Average |
| Return On Equity | -0.6 | -0.31 |
| Return On Asset | -0.2 | -0.14 |
| Profit Margin | (2.41) % | (1.27) % |
| Operating Margin | (2.15) % | (5.51) % |
| Current Valuation | 310.65 M | 16.62 B |
| Shares Outstanding | 45.81 M | 571.82 M |
| Shares Owned By Insiders | 6.56 % | 10.09 % |
| Shares Owned By Institutions | 79.84 % | 39.21 % |
| Number Of Shares Shorted | 9.06 M | 4.71 M |
| Price To Earning | 25.51 X | 28.72 X |
| Price To Book | 0.56 X | 9.51 X |
| Price To Sales | 1.78 X | 11.42 X |
| Revenue | 227.04 M | 9.43 B |
| Gross Profit | 182.5 M | 27.38 B |
| EBITDA | (484.39 M) | 3.9 B |
| Net Income | (547.03 M) | 570.98 M |
| Cash And Equivalents | 1.32 B | 2.7 B |
| Cash Per Share | 0.84 X | 5.01 X |
| Total Debt | 438.77 M | 5.32 B |
| Debt To Equity | 0.03 % | 48.70 % |
| Current Ratio | 11.84 X | 2.16 X |
| Book Value Per Share | 13.17 X | 1.93 K |
| Cash Flow From Operations | (319.58 M) | 971.22 M |
| Short Ratio | 4.28 X | 4.00 X |
| Earnings Per Share | (10.54) X | 3.12 X |
| Target Price | 8.6 | |
| Number Of Employees | 834 | 18.84 K |
| Beta | 1.24 | -0.15 |
| Market Capitalization | 404.49 M | 19.03 B |
| Total Asset | 1.38 B | 29.47 B |
| Retained Earnings | (5.84 B) | 9.33 B |
| Working Capital | 495.48 M | 1.48 B |
| Current Asset | 10.07 B | 9.34 B |
Note: Disposition of 454 shares by Mark Dmytruk of Ginkgo Bioworks subject to Rule 16b-3 [view details]
Ginkgo Bioworks Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Ginkgo . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Ginkgo Bioworks Buy or Sell Advice
When is the right time to buy or sell Ginkgo Bioworks Holdings? Buying financial instruments such as Ginkgo Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Ginkgo Bioworks in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Funds Thematic Idea Now
Consumer Funds
Funds or Etfs that invest in consumer products such as packaged goods, clothing, food, beverages and retail services. The Consumer Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Ginkgo Bioworks Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. If investors know Ginkgo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ginkgo Bioworks listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.54) | Revenue Per Share | Quarterly Revenue Growth 0.262 | Return On Assets | Return On Equity |
The market value of Ginkgo Bioworks Holdings is measured differently than its book value, which is the value of Ginkgo that is recorded on the company's balance sheet. Investors also form their own opinion of Ginkgo Bioworks' value that differs from its market value or its book value, called intrinsic value, which is Ginkgo Bioworks' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ginkgo Bioworks' market value can be influenced by many factors that don't directly affect Ginkgo Bioworks' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ginkgo Bioworks' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ginkgo Bioworks is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ginkgo Bioworks' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.